The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series

Anakinra used late in the disease course led to a rapid and sustained improvement in clinical and biological inflammation. Our retrospective analysis did show neither a striking nor a rapid decrease of coronary dilatations and we cannot determine if anakinra itself had an effect on coronary artery dimensions.